CIM
IMGN

Contravisory Investment Management’s Immunogen Inc IMGN Stock Holding History

Contravisory Investment Management’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-73
Closed – – 474
2017
Q4 		$0 Hold
73
– – ﹤0.01% 543
2017
Q3 		$1K Buy
+73
New +$485 ﹤0.01% 457

Other funds holding IMGN

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Contravisory Investment Management's IMGN Position: Q1 2018 in Review

Contravisory Investment Management sold out of Immunogen Inc (IMGN) in Q1 2018, closing a stake of 73 shares.

Contravisory Investment Management first reported a position in IMGN in Q3 2017 and held it in 2 quarters. The position peaked at $1K in Q3 2017. 204 funds tracked by Wall St. Rank hold IMGN as of Q1 2018.

  • Contravisory Investment Management reported no remaining Immunogen Inc position as of Q1 2018 after selling out during the quarter.
  • Contravisory Investment Management sold 73 Immunogen Inc shares in Q1 2018.
  • Contravisory Investment Management first reported a position in Immunogen Inc in Q3 2017 and held it in 2 quarters.
  • Contravisory Investment Management's Immunogen Inc position peaked at $1K in Q3 2017.
  • 204 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2018.

Based on Contravisory Investment Management's 13F filing for Q1 2018, filed 9 Apr 2018.